{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:46:00Z","timestamp":1791333960656,"version":"4.3.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The 2009 \u201cswine flu\u201d pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound development of new vaccine platform technologies with respect to prophylactic use in the population, including DNA vaccines. These vaccines are particularly well suited for global pandemic responses as the DNA format is temperature stable and the production process is cheap and rapid. Here, we show that by targeting influenza antigens directly to antigen presenting cells (APC), DNA vaccine efficacy equals that of conventional technologies. A single dose of naked DNA encoding hemagglutinin (HA) from influenza\/A\/California\/2009 (H1N1), linked to a targeting moiety directing the vaccine to major histocompatibility complex class II (MHCII) molecules, raised similar humoral immune responses as the adjuvanted split virion vaccine Pandemrix, widely administered in the 2009 pandemic. Both vaccine formats rapidly induced serum antibodies that could protect mice already 8 days after a single immunization, in contrast to the slower kinetics of a seasonal trivalent inactivated influenza vaccine (TIV). Importantly, the DNA vaccine also elicited cytotoxic T-cell responses that reduced morbidity after vaccination, in contrast to very limited T-cell responses seen after immunization with Pandemrix and TIV. These data demonstrate that DNA vaccines has the potential as a single dose platform vaccine, with rapid protective effects without the need for adjuvant, and confirms the relevance of naked DNA vaccines as candidates for pandemic preparedness.<\/jats:p>","DOI":"10.3389\/fimmu.2021.747032","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T13:34:05Z","timestamp":1633872845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief"],"prefix":"10.3389","volume":"12","author":[{"given":"Tor Kristian","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Bodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Oftung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Bogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Mjaaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnveig","family":"Gr\u00f8deland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0174-z","article-title":"Moving Tuberculosis Vaccines From Theory to Practice","volume":"19","author":"Andersen","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704507114","article-title":"Simply Put: Vaccination Saves Lives","volume":"114","author":"Orenstein","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e30018","DOI":"10.1371\/journal.pone.0030018","article-title":"Effect of Vaccines and Antivirals During the Major 2009 A(H1N1) Pandemic Wave in Norway\u2013and the Influence of Vaccination Timing","volume":"7","author":"Blasio","year":"2012","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy633","article-title":"Influenza Vaccines: Good, But We Can Do Better","volume":"219","author":"Paules","year":"2019","journal-title":"J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/1471-2458-11-932","article-title":"Vaccination Against 2009 Pandemic H1N1 in a Population Dynamical Model of Vancouver, Canada: Timing Is Everything","volume":"11","author":"Conway","year":"2011","journal-title":"BMC Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1002964","DOI":"10.1371\/journal.pcbi.1002964","article-title":"Optimal Vaccine Allocation for the Early Mitigation of Pandemic Influenza","volume":"9","author":"Matrajt","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.043","article-title":"Optimal Allocation of Pandemic Influenza Vaccine Depends on Age, Risk and Timing","volume":"26","author":"Mylius","year":"2008","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4529","article-title":"Advances in the Development of Influenza Virus Vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432","article-title":"DNA Vaccines: Ready for Prime Time","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2016.06.045","article-title":"Influenza Nucleoprotein DNA Vaccination by a Skin Targeted, Dry Coated, Densely Packed Microprojection Array (Nanopatch) Induces Potent Antibody and CD8(+) T Cell Responses","volume":"237","author":"Fernando","year":"2016","journal-title":"J Control Release"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.69","article-title":"DNA Vaccination in the Skin Using Microneedles Improves Protection Against Influenza","volume":"20","author":"Song","year":"2012","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24702","article-title":"Tolerability of Intramuscular and Intradermal Delivery by CELLECTRA((R)) Adaptive Constant Current Electroporation Device in Healthy Volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e59340","DOI":"10.1371\/journal.pone.0059340","article-title":"DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses After Rad5 Boost in a Randomized Clinical Trial","volume":"8","author":"Graham","year":"2013","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01568","article-title":"A Review of DNA Vaccines Against Influenza","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and Immunogenicity of a Two-Dose Heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccine Regimen in Adults in Europe (EBOVAC2): A Randomised, Observer-Blind, Participant-Blind, Placebo-Controlled, Phase 2 Trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030190","article-title":"Development of Pandemic Vaccines: ERVEBO Case Study","volume":"9","author":"Wolf","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.10.019","article-title":"DNA Vaccines Increase Immunogenicity of Idiotypic Tumor Antigen by Targeting Novel Fusion Proteins to Antigen-Presenting Cells","volume":"13","author":"Fredriksen","year":"2006","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300504","article-title":"DNA Vaccine That Targets Hemagglutinin to MHC Class II Molecules Rapidly Induces Antibody-Mediated Protection Against Influenza","volume":"191","author":"Grodeland","year":"2013","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600893","article-title":"Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination","volume":"197","author":"Grodeland","year":"2016","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e80008","DOI":"10.1371\/journal.pone.0080008","article-title":"The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype","volume":"8","author":"Grodeland","year":"2013","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445080","article-title":"Vaccine Molecules Targeting Xcr1 on Cross-Presenting DCs Induce Protective CD8+ T-Cell Responses Against Influenza Virus","volume":"45","author":"Fossum","year":"2015","journal-title":"Eur J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00367","article-title":"Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines","volume":"6","author":"Grodeland","year":"2015","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4049\/immunohorizons.1700038","article-title":"The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules","volume":"2","author":"Braathen","year":"2018","journal-title":"Immunohorizons"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1029919","article-title":"Efficient Vaccine Against Pandemic Influenza: Combining DNA Vaccination and Targeted Delivery to MHC Class II Molecules","volume":"14","author":"Grodeland","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e01156","DOI":"10.1128\/mBio.01156-15","article-title":"A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A Virus","volume":"6","author":"Frank","year":"2015","journal-title":"MBio"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2250","DOI":"10.3791\/2250","article-title":"Antigen Specific Killing Assay Using CFSE Labeled Target Cells","author":"Durward","year":"2010","journal-title":"J Vis Exp"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274","article-title":"T-Cell Quality in Memory and Protection: Implications for Vaccine Design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030551","article-title":"Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery","volume":"8","author":"Francis","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8764","DOI":"10.1038\/s41598-020-65059-0","article-title":"Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines\/Immunoprophylaxis in Animals Including Transchromosomic Bovines","volume":"10","author":"Mucker","year":"2020","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral Vector-Based Influenza Vaccines","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1038\/s41598-020-61730-8","article-title":"Modification of Adenovirus Vaccine Vector-Induced Immune Responses by Expression of a Signalling Molecule","volume":"10","author":"Rollier","year":"2020","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA Vaccine Vectors, non-Mechanical Delivery Methods, and Molecular Adjuvants to Increase Immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and Immunogenicity of INO-4800 DNA Vaccine Against SARS-CoV-2: A Preliminary Report of an Open-Label, Phase 1 Clinical Trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01340-17","article-title":"A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice Against H7 Influenza","volume":"91","author":"Andersen","year":"2017","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701088","article-title":"Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity Against Influenza","volume":"200","author":"Anderson","year":"2018","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-110-3_27","article-title":"Safety Assessment of Biolistic DNA Vaccination","volume":"940","author":"Langer","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B41","article-title":"The Uptake and Fate of Exogenous Cellular DNA in Mammalian Cells","volume":"123","author":"Strain","year":"2006","journal-title":"Dev Biol (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2174\/156652321403140819122538","article-title":"Improving DNA Vaccine Performance Through Vector Design","volume":"14","author":"Williams","year":"2014","journal-title":"Curr Gene Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301537","article-title":"Intramuscular Plasmid DNA Injection can Accelerate Autoimmune Responses","volume":"8","author":"MacColl","year":"2001","journal-title":"Gene Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0222178","DOI":"10.1371\/journal.pone.0222178","article-title":"Safety and Immunogenicity of Investigational Seasonal Influenza Hemagglutinin DNA Vaccine Followed by Trivalent Inactivated Vaccine Administered Intradermally or Intramuscularly in Healthy Adults: An Open-Label Randomized Phase 1 Clinical Trial","volume":"14","author":"Carter","year":"2019","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered With a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e0202753","DOI":"10.1371\/journal.pone.0202753","article-title":"Safety and Tolerability of HIV-1 Multiantigen pDNA Vaccine Given With IL-12 Plasmid DNA via Electroporation, Boosted With a Recombinant Vesicular Stomatitis Virus HIV Gag Vaccine in Healthy Volunteers in a Randomized, Controlled Clinical Trial","volume":"13","author":"Elizaga","year":"2018","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22129","article-title":"Clinical Trial in Healthy Malaria-Naive Adults to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of MuStDO5, a Five-Gene, Sporozoite\/Hepatic Stage Plasmodium Falciparum DNA Vaccine Combined With Escalating Dose Human GM-CSF DNA","volume":"8","author":"Richie","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the Effect of AS03 Adjuvant on the Plasma Cell Repertoire Following Ph1n1 Influenza Vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00321","article-title":"DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce\u00a0Influenza-Specific CD8(+) T Cell Responses, Enabling Faster Resolution of Influenza Disease","volume":"7","author":"Lambert","year":"2016","journal-title":"Front Immunol"},{"key":"B51","volume-title":"Guideline on Influenza Vaccines: Non-Clinical and Clinical Module. EMA\/CHMP\/VWP\/457259\/2014","year":"2016"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22908","article-title":"Correlates of Protection to Influenza Virus, Where do We Go From Here","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.850036","article-title":"The Emergence of H7N9 Viruses: A Chance to Redefine Correlates of Protection for Influenza Virus Vaccines","volume":"12","author":"Krammer","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00104","article-title":"A Mini Review of the Zoonotic Threat Potential of Influenza Viruses, Coronaviruses, Adenoviruses, and Enteroviruses","volume":"6","author":"Bailey","year":"2018","journal-title":"Front Public Health"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0320-6","article-title":"Human CD8(+) T Cell Cross-Reactivity Across Influenza A, B and C Viruses","volume":"20","author":"Koutsakos","year":"2019","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.747032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T13:34:09Z","timestamp":1633872849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.747032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2021.747032"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.747032","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"747032"}}